Home › Companies › VIR BIOTECHNOLOGY INC. › 2023-2024
Compiled from SEC Form N-PX filings and VIR BIOTECHNOLOGY INC.’s Form 8-K, filed May 29, 2024 (Item 5.07 on EDGAR). Page generated October 14, 2026.
Meeting of May 29, 2024: 6 items on VIR BIOTECHNOLOGY INC.’s Form 8-K, filed May 29, 2024: 4 elected · 2 approved.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore VIR BIOTECHNOLOGY INC. in the interactive database Compare manager voting policies
These tallies are VIR BIOTECHNOLOGY INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 29, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Marianne De Backer, M.Sc., Ph.D., MBA | 105,598,679 | -- | -- | 1,121,748 | 12,252,827 | 99% | Elected | — |
| Elect Director: Norbert Bischofberger, Ph.D. | 80,025,502 | -- | -- | 26,694,925 | 12,252,827 | 75% | Elected | — |
| Elect Director: Ramy Farid, Ph.D. | 106,416,937 | -- | -- | 303,490 | 12,252,827 | 99.7% | Elected | — |
| Elect Director: Robert Nelsen | 67,895,334 | -- | -- | 38,825,093 | 12,252,827 | 64% | Elected | — |
| 2. Advisory Vote on Executive Compensation | 83,922,789 | 22,639,307 | 158,331 | -- | 12,252,827 | 79% | Approved | — |
| 3. Ratification of Appointment of Independent Registered Public Accounting Firm | 118,125,237 | 679,046 | 168,971 | -- | 0 | 99.4% | Approved | — |
Source: VIR BIOTECHNOLOGY INC., Form 8-K, filed with the SEC on May 29, 2024 — read the filing on EDGAR.
Each item below shows how the 228 asset managers that disclosed a VIR BIOTECHNOLOGY INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Description as filed by funds: To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Marianne De Backer, M.Sc., Ph.D., MBA
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Marianne De Backer, M.Sc., Ph.D., MBA”): 105,598,679 for, 1,121,748 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class II Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 99% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 36,873,274 for, 471,471 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,290,711 | 0 | 0 | 0 | For |
| BlackRock | 11,421,008 | 0 | 0 | 0 | For |
| State Street | 5,172,209 | 0 | 0 | 6,627 | For |
| Fidelity | 1,901,340 | 0 | 0 | 0 | For |
| Charles Schwab | 769,430 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 769,000 | 0 | 0 | 0 | For |
| EA Series Trust | 458,044 | 0 | 0 | 0 | For |
| Dimensional | 0 | 0 | 0 | 435,704 | Withhold |
| Invesco | 325,204 | 0 | 0 | 0 | For |
| JPMorgan | 317,465 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 272,456 | 0 | 0 | 0 | For |
| Capital Group | 258,400 | 0 | 0 | 0 | For |
| Equitable | 228,770 | 0 | 0 | 0 | For |
| Jackson National | 195,800 | 0 | 0 | 13,984 | Mixed |
| TIAA | 205,358 | 0 | 0 | 0 | For |
| Global X | 197,630 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 183,773 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,230 | 0 | 0 | 0 | For |
| American Century | 147,112 | 0 | 0 | 0 | For |
| BNY Mellon | 126,525 | 0 | 0 | 0 | For |
| Royce | 102,900 | 0 | 0 | 0 | For |
| Principal | 98,106 | 0 | 0 | 0 | For |
| ProShares | 97,518 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,242 | 0 | 0 | 0 | For |
| Lincoln Financial | 70,300 | 0 | 0 | 5,566 | Mixed |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 4 wordings of this item as funds reported it.
75% Majority: yes · of votes cast
Description as filed by funds: To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Norbert Bischofberger, Ph.D.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Norbert Bischofberger, Ph.D.”): 80,025,502 for, 26,694,925 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class II Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 75% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 18,837,731 for, 18,507,014 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,290,711 | 0 | 0 | 0 | For |
| BlackRock | 0 | 0 | 0 | 11,421,008 | Withhold |
| State Street | 117,710 | 0 | 0 | 5,061,126 | Withhold |
| Fidelity | 1,830,943 | 0 | 0 | 70,397 | For |
| Charles Schwab | 0 | 0 | 0 | 769,430 | Withhold |
| BRIDGEWAY FUNDS INC | 769,000 | 0 | 0 | 0 | For |
| EA Series Trust | 458,044 | 0 | 0 | 0 | For |
| Dimensional | 435,704 | 0 | 0 | 0 | For |
| Invesco | 325,204 | 0 | 0 | 0 | For |
| JPMorgan | 317,465 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 272,456 | 0 | 0 | 0 | For |
| Capital Group | 258,400 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 228,770 | Withhold |
| Jackson National | 209,784 | 0 | 0 | 0 | For |
| TIAA | 205,358 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 197,630 | Withhold |
| Direxion Shares ETF Trust | 183,773 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 148,230 | Withhold |
| American Century | 147,112 | 0 | 0 | 0 | For |
| BNY Mellon | 126,525 | 0 | 0 | 0 | For |
| Royce | 102,900 | 0 | 0 | 0 | For |
| Principal | 98,106 | 0 | 0 | 0 | For |
| ProShares | 97,518 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,242 | 0 | 0 | 0 | For |
| Lincoln Financial | 5,566 | 0 | 0 | 70,300 | Mixed |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.7% Majority: yes · of votes cast
Description as filed by funds: To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Ramy Farid, Ph.D.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Ramy Farid, Ph.D.”): 106,416,937 for, 303,490 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class II Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 99.7% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 37,335,155 for, 9,590 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,290,711 | 0 | 0 | 0 | For |
| BlackRock | 11,421,008 | 0 | 0 | 0 | For |
| State Street | 5,178,836 | 0 | 0 | 0 | For |
| Fidelity | 1,901,340 | 0 | 0 | 0 | For |
| Charles Schwab | 769,430 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 769,000 | 0 | 0 | 0 | For |
| EA Series Trust | 458,044 | 0 | 0 | 0 | For |
| Dimensional | 435,704 | 0 | 0 | 0 | For |
| Invesco | 325,204 | 0 | 0 | 0 | For |
| JPMorgan | 317,465 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 272,456 | 0 | 0 | 0 | For |
| Capital Group | 258,400 | 0 | 0 | 0 | For |
| Equitable | 228,770 | 0 | 0 | 0 | For |
| Jackson National | 209,784 | 0 | 0 | 0 | For |
| TIAA | 205,358 | 0 | 0 | 0 | For |
| Global X | 197,630 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 183,773 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,230 | 0 | 0 | 0 | For |
| American Century | 147,112 | 0 | 0 | 0 | For |
| BNY Mellon | 126,525 | 0 | 0 | 0 | For |
| Royce | 102,900 | 0 | 0 | 0 | For |
| Principal | 98,106 | 0 | 0 | 0 | For |
| ProShares | 97,518 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,242 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,866 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 4 wordings of this item as funds reported it.
64% Majority: yes · of votes cast
Description as filed by funds: To elect the following four nominees for director to hold office until the 2027 Annual Meeting of Stockholders, and until their successor is duly elected and qualified, or until their earlier death, resignation or removal: Robert Nelsen
VIR BIOTECHNOLOGY INC.’s own tally for this item (“Elect Director: Robert Nelsen”): 67,895,334 for, 38,825,093 withheld, per its Form 8-K filed May 29, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Election of Directors The Company's stockholders elected the four persons listed below as Class II Directors, each to serve until the Company's 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resignation or remo…”
Support: 64% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 12,382,165 for, 24,962,580 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,221,311 | 0 | 0 | 69,400 | For |
| BlackRock | 0 | 0 | 0 | 11,421,008 | Withhold |
| State Street | 52,497 | 0 | 0 | 5,126,339 | Withhold |
| Fidelity | 0 | 0 | 0 | 1,901,340 | Withhold |
| Charles Schwab | 0 | 0 | 0 | 769,430 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 769,000 | Withhold |
| EA Series Trust | 0 | 0 | 0 | 458,044 | Withhold |
| Dimensional | 0 | 0 | 0 | 435,704 | Withhold |
| Invesco | 0 | 0 | 0 | 325,204 | Withhold |
| JPMorgan | 0 | 0 | 0 | 317,465 | Withhold |
| Columbia Threadneedle | 0 | 0 | 0 | 272,456 | Withhold |
| Capital Group | 0 | 0 | 0 | 258,400 | Withhold |
| Equitable | 0 | 0 | 0 | 228,770 | Withhold |
| Jackson National | 0 | 0 | 0 | 209,784 | Withhold |
| TIAA | 0 | 0 | 0 | 205,358 | Withhold |
| Global X | 0 | 0 | 0 | 197,630 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 183,773 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 148,230 | Withhold |
| American Century | 0 | 0 | 0 | 147,112 | Withhold |
| BNY Mellon | 0 | 0 | 0 | 126,525 | Withhold |
| Royce | 102,900 | 0 | 0 | 0 | For |
| Principal | 0 | 0 | 0 | 98,106 | Withhold |
| ProShares | 0 | 0 | 0 | 97,518 | Withhold |
| ALPS ETF Trust | 0 | 0 | 0 | 95,242 | Withhold |
| Lincoln Financial | 0 | 0 | 0 | 75,866 | Withhold |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Combines 11 wordings of this item as funds reported it.
79% Approved · of votes cast
Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's named executive officers.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“2. Advisory Vote on Executive Compensation”): 83,922,789 for, 22,639,307 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory basis, the compensation of the Company's named executive officers.”
Support: 79% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,221,311 | 69,400 | 0 | 0 | For |
| BlackRock | 11,421,008 | 0 | 0 | 0 | For |
| State Street | 52,497 | 5,126,339 | 0 | 0 | Against |
| Fidelity | 70,397 | 1,830,943 | 0 | 0 | Against |
| Charles Schwab | 0 | 769,430 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 769,000 | 0 | 0 | Against |
| EA Series Trust | 0 | 458,044 | 0 | 0 | Against |
| Dimensional | 0 | 435,704 | 0 | 0 | Against |
| Invesco | 0 | 325,204 | 0 | 0 | Against |
| JPMorgan | 0 | 317,465 | 0 | 0 | Against |
| Columbia Threadneedle | 0 | 272,456 | 0 | 0 | Against |
| Capital Group | 0 | 258,400 | 0 | 0 | Against |
| Equitable | 130,540 | 98,230 | 0 | 0 | Mixed |
| Jackson National | 0 | 209,784 | 0 | 0 | Against |
| TIAA | 0 | 205,358 | 0 | 0 | Against |
| Global X | 0 | 197,630 | 0 | 0 | Against |
| Direxion Shares ETF Trust | 0 | 183,773 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 148,230 | 0 | 0 | 0 | For |
| American Century | 0 | 147,112 | 0 | 0 | Against |
| BNY Mellon | 0 | 126,525 | 0 | 0 | Against |
| Royce | 0 | 0 | 102,900 | 0 | Abstain |
| Principal | 0 | 98,106 | 0 | 0 | Against |
| ProShares | 0 | 97,518 | 0 | 0 | Against |
| ALPS ETF Trust | 0 | 95,242 | 0 | 0 | Against |
| Lincoln Financial | 0 | 75,866 | 0 | 0 | Against |
Fund voting reports, all 72 managers: 24,307,393 for, 12,926,308 against, 112,490 abstained. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD | 16,684,041 | 0 | 0 | 0 | For |
| ARCH Venture Management, LLC | 12,916,663 | 0 | 0 | 0 | For |
| State Street | 52,497 | 6,815,908 | 0 | 0 | Against |
| BlackRock | 3,742,616 | 115,175 | 0 | 0 | For |
| BAILLIE GIFFORD & CO LTD | 3,821,033 | 0 | 0 | 0 | For |
| Citadel | 2,186,252 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 1,921,289 | 0 | 0 | Against |
| Bill & Melinda Gates Foundation | 1,559,142 | 0 | 0 | 0 | For |
| Renaissance | 0 | 877,147 | 0 | 0 | Against |
| Northern Trust | 837,968 | 4,320 | 0 | 0 | For |
| Charles Schwab | 0 | 828,980 | 0 | 0 | Against |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 810,700 | 0 | 0 | Against |
| PARAMETRIC PORTFOLIO ASSOCIATES LLC | 0 | 774,035 | 0 | 0 | Against |
| MELLON INVESTMENTS Corp | 0 | 684,676 | 0 | 0 | Against |
| ORBIMED ADVISORS LLC | 0 | 640,000 | 0 | 0 | Against |
| DE Shaw | 0 | 606,911 | 0 | 0 | Against |
| PRINCIPAL GLOBAL INVESTORS | 0 | 462,030 | 0 | 0 | Against |
| Invesco | 0 | 368,615 | 0 | 0 | Against |
| JPMorgan | 0 | 365,102 | 0 | 0 | Against |
| BNY Mellon | 0 | 324,684 | 0 | 0 | Against |
| Capital Group | 90 | 258,400 | 0 | 0 | Against |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 0 | 244,189 | 0 | 0 | Against |
| NORDEA INVESTMENT MANAGEMENT AB | 0 | 235,664 | 0 | 0 | Against |
| Goldman Sachs | 84,729 | 144,645 | 0 | 0 | Mixed |
| Nuveen | 0 | 208,300 | 0 | 0 | Against |
Institutional-manager reports, all 179 managers: 42,348,681 for, 19,875,191 against, 41 not voted. Showing the 25 largest; see all in the interactive database.
Combines 5 wordings of this item as funds reported it.
99.4% Approved · of votes cast
Description as filed by funds: To ratify the appointment by the Audit Committee of the Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.
VIR BIOTECHNOLOGY INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Public Accounting Firm”): 118,125,237 for, 679,046 against — passed, per its Form 8-K filed May 29, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Ratification of Appointment of Independent Registered Public Accounting Firm The Company's stockholders ratified the appointment by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending …”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 73 asset managers below reported 36,877,111 for, 458,044 against, 9,590 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 12,290,711 | 0 | 0 | 0 | For |
| BlackRock | 11,421,008 | 0 | 0 | 0 | For |
| State Street | 5,178,836 | 0 | 0 | 0 | For |
| Fidelity | 1,901,340 | 0 | 0 | 0 | For |
| Charles Schwab | 769,430 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 769,000 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 458,044 | 0 | 0 | Against |
| Dimensional | 435,704 | 0 | 0 | 0 | For |
| Invesco | 325,204 | 0 | 0 | 0 | For |
| JPMorgan | 317,465 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 272,456 | 0 | 0 | 0 | For |
| Capital Group | 258,400 | 0 | 0 | 0 | For |
| Equitable | 228,770 | 0 | 0 | 0 | For |
| Jackson National | 209,784 | 0 | 0 | 0 | For |
| TIAA | 205,358 | 0 | 0 | 0 | For |
| Global X | 197,630 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 183,773 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 148,230 | 0 | 0 | 0 | For |
| American Century | 147,112 | 0 | 0 | 0 | For |
| BNY Mellon | 126,525 | 0 | 0 | 0 | For |
| Royce | 102,900 | 0 | 0 | 0 | For |
| Principal | 98,106 | 0 | 0 | 0 | For |
| ProShares | 97,518 | 0 | 0 | 0 | For |
| ALPS ETF Trust | 95,242 | 0 | 0 | 0 | For |
| Lincoln Financial | 75,866 | 0 | 0 | 0 | For |
Showing the 25 largest of 73 asset managers. See all 73 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 135,843,560 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 9.05% |
| 2 | BlackRock | 8.41% |
| 3 | State Street | 3.81% |
| 4 | Fidelity | 1.40% |
| 5 | Charles Schwab | 0.57% |
| 6 | BRIDGEWAY FUNDS INC | 0.57% |
| 7 | EA Series Trust | 0.34% |
| 8 | Dimensional | 0.32% |
| 9 | Invesco | 0.24% |
| 10 | JPMorgan | 0.23% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | SB INVESTMENT ADVISERS (UK) LTD | 12.28% |
| 2 | ARCH Venture Management, LLC | 9.51% |
| 3 | State Street | 5.06% |
| 4 | BlackRock | 2.84% |
| 5 | BAILLIE GIFFORD & CO LTD | 2.81% |
| 6 | Citadel | 1.61% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.41% |
| 8 | Bill & Melinda Gates Foundation | 1.15% |
| 9 | Renaissance | 0.65% |
| 10 | Northern Trust | 0.62% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| SVF Endurance (Cayman) Ltd. | 12.28% | DEF14A |
| BlackRock | 11.75% | 13F |
| Robert Nelsen | 10.00% | DEF14A |
| Entities affiliated with ARCH Venture Partners, L.P. | 9.51% | DEF14A |
| Vanguard Group | 9.42% | 13F |
| Glaxo Group Limited | 6.29% | DEF14A |
| State Street | 5.20% | 13F |
| George Scangos, Ph.D. | 3.39% | DEF14A |
| FMR (Fidelity) | 2.68% | 13F |
| Citadel Advisors | 2.55% | 13F |
Percentages above are of 135,843,560 shares outstanding, as reported by VIR BIOTECHNOLOGY INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VIR BIOTECHNOLOGY INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.
At VIR BIOTECHNOLOGY INC.'s shareholder meeting held May 29, 2024, in the 2023-2024 proxy season, 228 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 1,650 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's named executive officers. — VIR BIOTECHNOLOGY INC.'s filing reports the proposal as approved, with 79% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: VIR BIOTECHNOLOGY INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 29, 2024.
VIR BIOTECHNOLOGY INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.